ACE2 and type 2 diabetes mellitus: Several mechanisms are responsible for poor prognosis in diabetic patients with COVID-19; however, the influence of the pharmaceuticals used for the treatment of SARS-CoV-2 infection (corticosteroids, lopinavir, and ritonavir) may contribute to the deterioration of glycemic control in people with type 2 diabetes mellitus and, thus, induce additional impairment of the innate immune response, promote the production of proinflammatory cytokines, and intensify a decrease in the expression of ACE2 [71].